Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19595600rdf:typepubmed:Citationlld:pubmed
pubmed-article:19595600lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:19595600lifeskim:mentionsumls-concept:C0456387lld:lifeskim
pubmed-article:19595600lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:19595600pubmed:issue15lld:pubmed
pubmed-article:19595600pubmed:dateCreated2009-7-21lld:pubmed
pubmed-article:19595600pubmed:abstractTextEndothelial dysfunction and consequent reduction of biosynthesis of endogenous nitric oxide (NO) play an important pathogenetic role in the cardiovascular complications associated with type II diabetes. In this work, the hybrid drugs 3a and 3b, nitrooxymethylbenzoate-derivatives of 1 (which is a hydroxylated active metabolite of glibenclamide 2), are reported. The pharmacodynamic characterization of 3b showed that its hypoglycaemic activity is enriched with additional NO-donor effects, conferring vasorelaxing and anti-platelet properties of potentially great usefulness for diabetes-related cardiovascular disorders.lld:pubmed
pubmed-article:19595600pubmed:languageenglld:pubmed
pubmed-article:19595600pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19595600pubmed:citationSubsetIMlld:pubmed
pubmed-article:19595600pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19595600pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19595600pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19595600pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19595600pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19595600pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19595600pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19595600pubmed:statusMEDLINElld:pubmed
pubmed-article:19595600pubmed:monthAuglld:pubmed
pubmed-article:19595600pubmed:issn1464-3391lld:pubmed
pubmed-article:19595600pubmed:authorpubmed-author:MarchettiPier...lld:pubmed
pubmed-article:19595600pubmed:authorpubmed-author:BalsamoAldoAlld:pubmed
pubmed-article:19595600pubmed:authorpubmed-author:CalderoneVinc...lld:pubmed
pubmed-article:19595600pubmed:authorpubmed-author:TestaiLaraLlld:pubmed
pubmed-article:19595600pubmed:authorpubmed-author:RapposelliSim...lld:pubmed
pubmed-article:19595600pubmed:authorpubmed-author:BreschiMaria...lld:pubmed
pubmed-article:19595600pubmed:authorpubmed-author:MartelliAlmaAlld:pubmed
pubmed-article:19595600pubmed:authorpubmed-author:DigiacomoMari...lld:pubmed
pubmed-article:19595600pubmed:authorpubmed-author:TorriScillaSlld:pubmed
pubmed-article:19595600pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19595600pubmed:day1lld:pubmed
pubmed-article:19595600pubmed:volume17lld:pubmed
pubmed-article:19595600pubmed:ownerNLMlld:pubmed
pubmed-article:19595600pubmed:authorsCompleteYlld:pubmed
pubmed-article:19595600pubmed:pagination5426-32lld:pubmed
pubmed-article:19595600pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:19595600pubmed:meshHeadingpubmed-meshheading:19595600...lld:pubmed
pubmed-article:19595600pubmed:meshHeadingpubmed-meshheading:19595600...lld:pubmed
pubmed-article:19595600pubmed:meshHeadingpubmed-meshheading:19595600...lld:pubmed
pubmed-article:19595600pubmed:meshHeadingpubmed-meshheading:19595600...lld:pubmed
pubmed-article:19595600pubmed:meshHeadingpubmed-meshheading:19595600...lld:pubmed
pubmed-article:19595600pubmed:meshHeadingpubmed-meshheading:19595600...lld:pubmed
pubmed-article:19595600pubmed:meshHeadingpubmed-meshheading:19595600...lld:pubmed
pubmed-article:19595600pubmed:meshHeadingpubmed-meshheading:19595600...lld:pubmed
pubmed-article:19595600pubmed:meshHeadingpubmed-meshheading:19595600...lld:pubmed
pubmed-article:19595600pubmed:meshHeadingpubmed-meshheading:19595600...lld:pubmed
pubmed-article:19595600pubmed:meshHeadingpubmed-meshheading:19595600...lld:pubmed
pubmed-article:19595600pubmed:meshHeadingpubmed-meshheading:19595600...lld:pubmed
pubmed-article:19595600pubmed:meshHeadingpubmed-meshheading:19595600...lld:pubmed
pubmed-article:19595600pubmed:meshHeadingpubmed-meshheading:19595600...lld:pubmed
pubmed-article:19595600pubmed:meshHeadingpubmed-meshheading:19595600...lld:pubmed
pubmed-article:19595600pubmed:meshHeadingpubmed-meshheading:19595600...lld:pubmed
pubmed-article:19595600pubmed:meshHeadingpubmed-meshheading:19595600...lld:pubmed
pubmed-article:19595600pubmed:year2009lld:pubmed
pubmed-article:19595600pubmed:articleTitleNO-glibenclamide derivatives: prototypes of a new class of nitric oxide-releasing anti-diabetic drugs.lld:pubmed
pubmed-article:19595600pubmed:affiliationDipartimento di Psichiatria, Neurobiologia, Farmacologia, Biotecnologie, Università di Pisa, Via Bonanno, 6, I-56126 Pisa, Italy. calderone@farm.unipi.itlld:pubmed
pubmed-article:19595600pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:19595600lld:chembl